{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107416","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.442564+00:00","generated_at":"2026-05-17T15:00:41.695107+00:00","sec_items":["1.01","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Heron Therapeutics completes comprehensive refinancing, board expansion, and preferred stock issuance","bullets":["Refinancing closed Aug 12: repurchased $125M of 2026 notes for cash, exchanged $25M for 16.67M shares; issued $35M notes due 2031 at $33.25M.","Private placement raised ~$27.7M: 13.23M common shares at $1.50 and 524,141 Series A convertible preferred (convertible into 5.24M common at $1.50, subject to stockholder approval).","Cooperation Agreement with Rubric Capital expands board to 7 directors, appoints Rubric nominee, includes standstill until Feb 2026 or 30 days before 2026 annual meeting nomination deadline.","New Series A Convertible Preferred: $15 stated value, conversion price $1.50, senior to common on liquidation/dividends, no voting rights except on adverse charter changes.","Hercules term loan facility amended: up to $150M available with $110M funded on closing, includes PIK interest."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107416","json":"https://secwatch.observer/filing/0000950170-25-107416.json","markdown":"https://secwatch.observer/filing/0000950170-25-107416.md","text":"https://secwatch.observer/filing/0000950170-25-107416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017025107416/0000950170-25-107416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017025107416/hrtx-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:00:41.695107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b8ad4ab32ee7d99a72d6d9c36b03949678bb911","claim":"HERON THERAPEUTICS, INC. /DE/: Filing of Certificate of Designation of Series A Convertible Preferred Stock (effective 2025-08-11).","evidence_excerpt":"the Board authorized and the Company filed, on August 11, 2025, the Certificate of Designation of Rights, Preferences and Privileges (the “Certificate of Designation’) of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Convertible Preferred Stock”), with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017025107416/0000950170-25-107416-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}